- Home
- ELOG vs NRSN Comparison
ELOG vs NRSN Comparison
Compare ELOG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELOG | NRSN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.6M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELOG | NRSN |
|---|---|---|
| Price | $0.70 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $91.75 |
| AVG Volume (30 Days) | ★ 647.9K | 36.8K |
| Earning Date | 11-19-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $0.25 |
| 52 Week High | $2.83 | $7.50 |
Technical Indicators
Market Signals| Indicator | ELOG | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 31.32 |
| Support Level | $0.42 | $0.61 |
| Resistance Level | $1.01 | $7.50 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 2.62 | 24.85 |
Price Performance
Historical ComparisonAbout ELOG Eastern International Ltd. Ordinary Shares
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.